📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The list of literature references cited across the clinical summaries.
Why it exists. Claims in the clinical summaries must be traceable to their sources — published literature and the study reports. Module 2.7.5 is the bibliography that supports the arguments made in 2.5 and 2.7.
How it is produced here. It contains no new data. It is a distillation — it gathers, summarizes, and cross-references the underlying study reports and datasets into the shorter form a regulator reads first.
Format & governing standard. ICH M4E(R2) §2.7.5
| Field | Value |
|---|---|
| Document ID | M275 |
| Version | 1.0 |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Standard | ICH M4E(R2) §2.7.5 |
| Confidentiality | Confidential |
References cited in the Clinical Summary (2.7.1–2.7.4) and Clinical Overview (2.5).
[MOCK]placeholder citations representative of the field; full bibliographic details would be provided in an actual submission.
No comments yet. Be the first to say something!
| Version |
|---|
| Date |
|---|
| Author |
|---|
| Summary |
|---|
| 1.0 | 2026-06-29 | Medical Writing | Initial reference list |
[MOCK]Internal study reports: PROT-301, SAP-301, CSR-301, CSR-101/102/201, IB-001 (cross-referenced throughout Module 2).